These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3280129)

  • 1. Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease.
    Melamed E
    Clin Neuropharmacol; 1988 Feb; 11(1):77-82. PubMed ID: 3280129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular mechanisms of levodopa action in animal models of Parkinson's disease].
    Nowak P; Szczerbak G; Dabrowska J; Bortel A; Biedka I; Kostrzewa RM
    Neurol Neurochir Pol; 2006; 40(6):517-25. PubMed ID: 17199178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
    Melamed E; Hefti F; Wurtman RJ
    Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 10. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of motor complications in advanced Parkinson's disease.
    Melamed E; Ziv I; Djaldetti R
    Mov Disord; 2007 Sep; 22 Suppl 17():S379-84. PubMed ID: 18175400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing Parkinson's disease with continuous dopaminergic stimulation.
    Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
    CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic directions for Parkinson's disease.
    Fisher LJ; Gage FH
    Mol Med Today; 1995 Jul; 1(4):181-7. PubMed ID: 9415155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
    Kempster PA; Gibb WR; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.